Provided the regulatory role of TGF-β in the development of CRC and its metastatic process, different studies have validated this pathway as a valid target for metastatic CRC treatment and have facilitated the development of several strategies targeting TGF-β which are currently in preclinical or clinical trials [106]. The gene discussed is TGFB1; the disease is colorectal carcinoma.